|
|
|
| Research progress in clinical manifestations,prevention and treatment of common autoimmune encephalitis in children |
| LUO Xiaoying, JIANG Peifang
|
| Department of Neurology,The Children's Hospital affiliated to Zhejiang University School of Medicine,Hangzhou, Zhejiang 310052,China |
|
|
|
|
Abstract Autoimmune encephalitis is a kind of brain inflammation mediated by immune mechanism. Recent years have witnessed its higher incidence with the improvement of detection technologies and knowledge. Early diagnosis and treatment are the key to improve the prognosis of autoimmune encephalitis. However,the clinical manifestations of autoimmune encephalitis in children is not as typical as those in adults,and our expert consensus on autoimmune encephalitis is not fully applicable to children,which brings great challenge to clinical diagnosis and prevention. This article reviews the research into the prevalence,clinical manifestations,diagnosis,prevention and treatment of autoimmune encephalitis in children at home and aboard,so as to provide reference for its diagnosis and prevention.
|
|
Received: 15 November 2019
Revised: 02 January 2020
Published: 12 May 2020
|
|
|
|
|
|
[1] JMOR F, EMSLEY H C, FISCHER M,et al.The incidence of acute encephalitis syndrome in western industrialised and tropical countries[J]. Virol J,2008(5):134.
[2] VORA N M, HOLMAN R C, MEHAL J M, et al.Burden of encephalitis-associated hospitalizations in the United States, 1998-2010[J]. Neurology,2014,82(5):443-451.
[3] NOSADINI M, MOHAMMAD S S, RAMANATHAN S,et al.Immune therapy in autoimmune encephalitis: a systematic review[J].Expert Rev Neurother,2015,15(12): 1391-1419.
[4] CORSELLIS J A, GOLDBERG G J,NORTON A R.“Limbic encephalitis”and its association with carcinoma[J]. Brain,1968,91(3):481-496.
[5] DALMAU J, TÜZÜN E, WU H Y, et al. Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma[J]. Ann Neurol, 2007, 61(1):25-36.
[6] DUBEY D, PITTOCK S J, KELLY C R,et al.Autoimmune encephalitis epidemiology and a comparison to infectious encephalitis[J].Ann Neurol,2018, 83(1):166-177.
[7] GRAUS F, TITULAER M J, BALU R,et al.A clinical approach to diagnosis of autoimmune encephalitis[J]. Lancet Neurol,2016,15(4):391-404.
[8] 中华医学会神经病学分会.中国自身免疫性脑炎诊治专家共识[J].中华神经科杂志,2017,50(2):91-98.
[9] GRAUS F, DELATTRE J Y, ANTOINE J C,et al.Recommended diagnostic criteria for paraneoplastic neurological syndromes[J]. J Neurol Neurosurg Psychiatry,2004,75(8):1135-1140.
[10] GRAUS F, KEIME-GUIBERT F, RENE R, et al.Anti-Hu-asso-ciated paraneoplastic encephalomyelitis: analysis of 200 patients[J]. Brain, 2001,124(Pt6):1138-1148.
[11] LLAD�� A, MANNUCCI P,CARPENTIER A F,et al.Value of Hu antibody determinations in the follow-up of paraneoplastic neurologic syndromes[J]. Neurology, 2004,63(10):1947-1949.
[12] GABLE M S, SHERIFF H, DALMAU J,et al.The frequency of autoimmune N-methyl-D-aspartate receptor encephalitis surpasses that of individual viral etiologies in young individuals enrolled in the California Encephalitis Project[J].Clin Infect Dis, 2012,54(7):899-904.
[13] GOLD S M, WILLING A, LEYPOLDT F, et al.Sex differences in autoimmune disorders of the central nervous system[J]. Semin Immunopathol,2019,41(2):177-188.
[14] TITULAER M J, MCCRACKEN L, GABILONDO I,et al.Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study[J]. Lancet Neurol,2013,12(2):157-165.
[15] ESPOSITO S, PRINCIPI N, CALABRESI P, et al.An evolving redefinition of autoimmune encephalitis[J].Autoimmun Rev,2019,18(2):155-163.
[16] TRAYNELIS S F, WOLLMUTH L P, MCBAIN C J,et al.Glutamate receptor ion channels: structure, regulation, and function[J]. Pharmacol Rev, 2010,62(3):405-496.
[17] LAZAR-MOLNAR E, TEBO A E.Autoimmune NMDA receptor enc ephalitis[J].Clin Chim Acta,2015,438(1):90-97.
[18] MACDONALD J F, JACKSON M F, BEAZELY M A.Hippocampal long-term synaptic plasticity and signal amplification of NMDA receptors[J]. Crit Rev Neurobiol,2006,18(1/2):71-84.
[19] ZHANG L, WU M Q, HAO Z L, et al.Clinical characteristics, treatments, and outcomes of patients withanti-N-methyl-D-aspartate receptor encephalitis: a systematic review of reported cases[J]. Epilepsy Behav,2017,68:57-65.
[20] MOHAMMAD S S, FUNG V S, GRATTAN-SMITH P, et al.Move ment disorders in children with anti-NMDAR encephalitis and other autoimmune encephalopathies[J].Mov Disord,2014,29(12):1539-1542.
[21] HARUTYUNYAN G, HAUER L, DÜNSER M W, et al.Autoimm-une encephalitis at the neurological intensive care unit:etiologies, reasons for admission and survival[J].Neurocrit Care,2017,27(1):82-89.
[22] ZHANG Y, LIU G, JIANG M D, et al.Analysis of electroenceph alogram characteristics of anti-NMDA receptor encephalitis patients in China[J]. Clin Neurophysiol,2017,128(7):1227-1233.
[23] GELFADJ M.Autoimmune encephalitis after herpessimplexencephalitis: insights into pathogenesis[J].Lancet Neurol,2018,17(9):733-735.
[24] ARMANGUE T, SPATOLA M, VLAGEA A, et al.Frequency, symptoms, risk factors, and outcomes of autoimmune encephalitis after herpes simplex encephalitis: a prospective observational study and retrospective analysis[J].Lancet Neurol,2018,17(9):760-772.
[25] HOU R, WU J, HE D, et al.Anti-N-methyl-D-aspartate receptor encephalitis associated with reactivated Epstein-Barr virus infection in pediatric patients;three case reports[J].Medicine (Baltimore), 2019,98(20):e15726.
[26] RAMANATHAN S, DALE R C, BRILOT F.Anti-MOG antibody: the history, clinical phenotype, and pathogenicity of a serum biomarker for demyelination[J]. Autoimmun Rev,2016,15(4):307-324.
[27] HENNES E M, BAUMANN M, SCHANDA K, et al.Prognostic relevance of MOG antibodies in children with an acquired demyelinating syndrome[J]. Neurology,2017,89(9):900-908.
[28] VON BÜDINGEN H C, HAUSER S L, OUALLET J C, et al.Fron tline: epitope recognition on the myelin/oligodendrocyte glycoprotein differentially influences disease phenotype and antibody effector functions in autoimmune demyelination[J]. Eur J Immunol,2004,34(8):2072-2083.
[29] REINDL M, WATERS P.Myelin oligodendrocyte glycoprotein antibo- dies in neurological disease[J].Nat Rev Neurol,2019,15(2):89-102.
[30] JURYNCZYK M, MESSINA S, WOODHALL M R, et al.Clinical presentation and prognosis in MOG-antibody disease: a UK study[J]. Brain, 2017,140(12):3128-3138.
[31] KRUER M C,HOEFTBERGER R,LIM K Y,et al.Aggressive course in encephalitis with opsoclonus, ataxia, chorea, and seizures: the first pediatric case of γ- aminobutyric acid type B receptor autoimmunity[J]. JAMA Neurol,2014,71(5):620-623.
[32] DALMAU J, ROSENFELD M R.Autoimmune encephalitis update[J].Neuro Oncol, 2014,16(6):771-778.
[33] NAGAI K, MAEKAWA T, TERASHIMA H, et al.Severe anti-GAD antibody-associated encephalitis after stem cell transplantation[J]. Brain Dev,2019,41(3):301-304.
[34] BÖRÖCZ K, HAYDEN Z, M��SZ��ROS V, et al.Autoimmune ence phalitis: possibilities in the laboratory investigation[J]. Orv Hetil,2018,159(3):107-112.
[35] TANAKA K, TANAKA M, IGARASHI S,et al.Trial to establish an animal model of paraneoplastic cerebellar degeneration with anti-Yo antibody. 2.Passive transfer of murine mononuclear cells activated with recombinant Yo protein to paraneoplastic cerebellar degeneration lymphocytes in severe combined immunodeficiency mice[J]. Clin Neurol Neurosurg, 1995,97(1):101-105.
[36] IRANI S R.“Moonlighting”surface antigens: a paradigm for autoa ntibody pathogenicity in neurology[J]. Brain, 2016,139(Pt2):304-306.
[37] ESPOSITOA S, PRINCIPIB N, CALABRESIC P, et al.An evol ving redefinition of autoimmune encephalitis[J].Autoimmun Rev,2019,18(2):155-163.
[38] DALE R C, GORMAN M P, LIM M.Autoimmune encephalitis in children: clinical phenomenology, therapeutics, and emerging challenges[J].Curr Opin Neurol,2017,30(3):334-344.
[39] STINGL C, CARDINALE K, VAN MATER H.An update on the treatment of pediatric autoimmune encephalitis[J].Curr Treatm Opt Rheumatol,2018,4(1):14-28. |
|
|
|
